Astrazeneca Ab

Antonio LLinas

Matti Juhani Lepistö

Martin Hemmerling

Karl Henrik Edman

Kenneth Lars Granberg

Karolina Lawitz

Lena Elisabeth Ripa

Mickael Mogemark

Hans Fredrik Emtenäs

Jonas Bostrõm

Karl Edman

This specification generally relates to 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds (including salts thereof). This specification also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including treatment methods and medicament preparations), and processes for making such a compound.

1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators

The invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof, wherein m, n, R, R, R, R, R, x and y are as defined herein. Compounds according to Formula I are pharmacologically effective as potassium channel inhibitors, in particular inhibitors of the acetylcholine operated inward rectifying potassium channel current (i.e. IKACh blockers), and are believed to be useful in the treatment of cardiac arrhythmias, in particular supraventricular tacharrhythmias, such as atrial fibrillation and atrial flutter.

Compounds and their use as IKACh blockers

Growing community of inventors

Mölndal, Sweden

Antonio LLinas